Mendis S. Stroke disability and rehabilitation of stroke: World Health Organization perspective. Intern J Stroke, 2013, 8(1): 3-4.

Royal College of Physicians. National Sentinel Stroke Clinical Audit 2010. Dublin, Ireland: Intercollegiate Stroke Working Party. 2011.

Feigin VL, Barker-Collo S, Parag V, Senior H, Lawes CM, Ratnasabapathy Y et al. Auckland Stroke Outcomes Study. Part 1: Gender, stroke types, ethnicity, and functional outcomes 5 years poststroke. Neurology, 2010, 75(18): 1597-607.

Van Peppen RP, Kwakkel G, Wood-Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker J. The impact of physical therapy on functional outcomes after stroke: what’s the evidence? Clin Rehabil, 2004, 18(8): 833-62.

British Psychological Society. Briefing paper 19: psychological services for stroke survivors and their families. Leicester: British Psychological Society. 2002.

Douiri A, Rudd AG, Wolfe CD. Prevalence of

post stroke cognitive impairment: South London Stroke Register 1995–2010. Stroke, 2013, 44(1): 138-45.

Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М., 2012.

Левин О.С., Васенина Е.Е., Трусова Н.А., Чимагомедова А.Ш. Современные подходы к диагностике и лечению постинсультных когнитивных нарушений. Пожилой пациент, 2016, 1(5): 9-16.

Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 1993, 43: 250-260.

Snaphaan L, De Leeuv E. Poststroke memory function in nondemented patients. Stroke, 2007, 38: 192-203.

Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol, 2009, 8(11): 1006-18.

Salvadori E, Pasi M, Poggesi A, Chiti G, Inzitari D, Pantoni L. Predictive value of MoCA in the acute phase of stroke on the diagnosis of midterm cognitive impairment. J Neurol, 2013, 260(9): 2220-7.

Pohjasvaara T, Erkinjuntti T, Vataja R et al. Dementia three months after stroke: baseline frequency and effect of different definitions for dementia in the Helsinki Aging Memory Study cohort. Stroke, 1997, 28: 785-92.

Kase CS, Wolf PA, Hayes KM et al. Intellectual decline after stroke. The Framingam study. Stroke, 1998, 29: 805-12.

Рasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol, 1997, 244: 135-42.

Hénon H, Pasquier F, Leys D. Poststroke dementia. Cerebrovasc Dis, 2006, 22: 61-70.

Захаров В.В. Когнитивные нарушения после инсульта. Нервные болезни, 2015, 2: 2-8.

Jorm A. The informant questionnare on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatrics, 2004, 16(3): 1-19.

Henon H, Durieu I, Lebert F et al. Influence of pre-stroke dementia on early and delayed mortality in stroke patients. J Neurol, 2003, 250(1): 10-6.

Вахнина Н.В., Никитина Л.Ю., Парфенов В.А. Постинсультные когнитивные нарушения. Журн неврол и психиатр им. С.С. Корсакова. Приложение «Инсульт», 2008, 22: 16-21.

Iemolo F, Duro G, Rizzo C, Castiglia L, Hachinski V, Caruso C. Pathophysiology of vascular dementia. Immun Ageing, 2009, 6: 13.

Nijsse B, Visser-Meily JMA, van Mierlo ML, Post MWM, de Kort PLM and van Heugten CM. Temporal Evolution of Poststroke Cognitive Impairment Using the Montreal Cognitive Assessment. Stroke, 2016 Nov 29, Epub ahead of print.

Климов Л.В., Парфенов В.А. Когнитивные нарушения в остром периоде ишемического инсульта. Неврол. журн., 2006, 11(Прил. 1): 53.

Вербицкая С.В., Парфенов В.А. Клинический опыт применения мемантина при постинсультной деменции. Неврол. журн., 2008, 13(4): 45.

Patel M, Coshall C, Rudd A et al. Natural history of cognitive impairmentafter stroke and factors associated with its recovery. Cerebrovasc Dis, 2001, 1(Suppl. 4): 9.

Боголепова А.Н. Критерии диагностики и прогноза ишемического инсульта (клинико-нейропсихологическое исследование). Автореф дис. … докт. мед. наук, М.: 2003, 289 с.

Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PMW, Teushl Y et al. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol, 2015, 22(2): 229-e16.

Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuro-pathological substrates of vascular dementia. J Neurol Sci, 2004, 226: 75-80.

Захаров В.В., Вахнина Н.В. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика, 2011, 2: 8-16.

Dong Y, Sharma VK, Chan BP et al. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for detection of vascular cognitive impairment after acute stroke. J Neurosci, 2010, 299(1–2): 15-8.

Robinson RG, Bolla-Wilson K, Kaplan E et al. Depression influences intellectual impairment in stroke patients. Br J Psychiatry, 1986, 148: 541-7.

Катунина Е.А., Беликова Л.П., Макарова А.А. Постинсультные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика, 2013, 2: 105-108.

Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med, 2003, 163: 1069-1075.

Diener H-C, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in pati ents with ischaemic stroke in the Prevention Regi men for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol, 2008, 7: 875-884.

Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PMW. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci, 2010, 299: 168-174.

Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation, 2013, 128(12): 1341-8.

Buchmayer F, Pleiner J, Elminger MW et al. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr, 2011, 161(3–4): 80-88.

Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin’s mode of action. J Neurol Sci, 2012, 322(1): 222-227.

Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. Neuromolecular Med, 2011, 13(4): 266-274.

Yurinskaya MM, Vinokurov MG, Astashkin EI, Grachev SV, Orekhova NS, Novikova AN, Sokolova IN. Calf blood hemodializate reduces neurotoxic effect of hydrogen peroxide on human neuroblastoma cells. Vestn Ross Akad Med Nauk, 2014, 9-10: 10-14.

Jansen W, Brueckner GW. Лечение хронической цереброваскулярной недостаточности с использованием драже Актовегин форте (двойное слепое, плацебо-контролируемое исследование). РМЖ, 2002, 10(12–13): 543-547.

Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Infusionstherapie mit Actovegin bei Patienten mit ptimar degenerativer Demenz vom Alzheimer Тур und Multiinfarkt-Demenz. Z. Geriatrie, 1992, 5: 46-55.

Oswald WD, Steger W, Oswald B et al. Increase of fluid cognitive components as an aspect in evaluation drug efficacy. A double-controlled study with Actovegin. Zeitschrift fur Geronto-psycho logie und Psichiatrie, 1991, 4(4): 209-220.

Saletu В, Grunberger J, Linzmayer L et al. EEG Brain Mapping and Psychometry in age-associated memory impairment after acute and 2-week infusion with the impairment after acute and 2-week infusion with the hemoderivative Actovegin: double-blind, placebo-controlled trials. Neuropsychobiology, 1990-1991, 24: 135-148.

Semlitsch HV, Anderer P, Saletu B et al. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment. Neurophychobiol, 1990-1991, 24: 49-56.

Захаров В.В., Сосина В.Б. Применение антигипоксантов в лечении когнитивных нарушений у больных сахарным диабетом. Неврол журн, 2008, 13(5): 39-44.

Деревянных Е.А., Бельская Г.Н., Кноль Е.В. и др. Опыт применения актовегина при лечении больных с когнитивными расстройствами в остром периоде инсульта. Журн неврол и психиатр им. С.С. Корсакова. Приложение «Инсульт», 2007, 20: 55-7.

Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U. A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. Dement Geriatr Cogn Dis Extra, 2013 Dec 14, 3(1): 459-67.

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment PSCI][ARTEMIDA]//https:// clinicaltrials.gov/ct2/show/results/NCT0158285 4?term=ARTEMIDA&rank=1§=X1256#all.https://clinicaltrials.gov/ct2/show/results/NCT0158285

Guekht A, Skoog I, Korczyn A, Zakharov V. A multicentre randomized placebo-controlled trial to assess the effect of deproteinized hemoderivate in patients with poststroke cognitive impairment (ARTEMIDA study). International Journal of Stroke, 2016, 11(3S): 41